What’s Next in the World of Email Automation?

Greg Norton is a Marketing Cloud Account Executive at Salesforce, and he shared his thoughts about what’s next in the world of email and automation,

“I could think of it in terms of three different buckets on what we’ll call a maturity model.

The first bucket is really the most basic level that’s expected of organizations to have today, and that’s to be able to use automation to send out emails, such as happy birthdays and different things like that.

That second bucket on the maturity model starts to connect different things like channels using social media and digital advertising, with email automation still being that main driver, and it’s the beginning of being able to connect that customer experience across their preferred channel, but not really in real time in moments that matter.

But what about that third bucket, that pinnacle that organizations nowadays are all trying to get to faster than the competition? It really comes down to making sure that you are sending out relevant engagements to all your customers at a one-on-one level across all touchpoints.

It really comes down to that value proposition of understanding what people need and want in real time, so you can respond in the moment before your competition does.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More